|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C215H347N61O65S |
|||
| Molecular Weight | 4858.49 | CAS No. | 320367-13-3 | |
| Solubility (25°C)* | In vitro | Water | 100 mg/mL (20.58 mM) | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro | Lixisenatide protects Ins-1 cells (a rat-derived β-cell line) from both lipid- and cytokine-induced apoptosis. More importantly, Lixisenatide also prevents lipotoxicity-induced insulin depletion in human islets and preserves insulin production, storage and pancreatic β-cell function in vitro. Binding studies in CHO-K1 cells overexpressing the human GLP-1 receptor show that Lixisenatide is a very potent and selective GLP-1 receptor agonist--the binding affinity of Lixisenatide (Ki = 1.33 ± 0.22 nM) is ∼ 4-times greater than that of human GLP-1 (Ki = 5.09 ± 1.19 nM). In more than 80 different binding assays, lixisenatide does not exhibit any relevant interaction with other potential drug targets, confirming its high selectivity for the GLP-1 receptor[3]. | ||
| In vivo | The half-life of lixisenatide is 2-4 hours, and it is classed as a short-acting GLP-1-receptor agonist, compared with the long-acting GLP-1-based peptides, liraglutide and albiglutide. Lixisenatide can significantly improve glucose-stimulated insulin secretion. In healthy normoglycemic dogs, single subcutaneous injections of lixisenatide produces dose-dependent reductions in plasma glucose after an oral glucose challenge and significantly reduces postprandial glucose excursions by 67% compared with placebo without increasing insulin concentrations. The effect of lixisenatide on postprandial blood glucose excursions in dogs is, at least in part, related to inhibition of gastric emptying and delayed intestinal glucose absorption. Dose-dependent reductions in plasma glucose after an oral glucose challenge have also been demonstrated in both the db/db mouse and ZDF rat. Importantly, this activity is glucose-dependent with no effect at physiological glucose concentrations. In db/db mice, chronic lixisenatide administration preventes the progressive deterioration in glucose tolerance observed in control animals and is associated with significant dose-dependent reductions in glycosylated hemoglobin (HbA1c). In ZDF rats, a continuous subcutaneous infusion of lixisenatide 50 μg/kg/day for 12 weeks significantly decreases basal blood glucose and improves oral glucose tolerance compared with control animals. It has no hypoglycemic effect and does not change HbA1c in normoglycemic rats. Lixisenatide can maintain beta cell mass and function through stimulation of islet cell proliferation and neogenesis, and inhibition of islet cell apoptosis[1]. Lixisenatide preserves pancreatic responsiveness in diabetic animals[3]. |
Protocol (from reference)
| Animal Study: |
|
|---|
References
|
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.